BioIndustry Ethics
BioIndustry Ethics by David L. Finegold, published by Elsevier S & T in 2005, offers a systematic and detailed examination of the ethical approaches adopted by biotech and pharmaceutical companies. This 384-page book addresses the ethical questions arising from the application of genetic and genomic technologies, which have significant implications for global health.
Readers will find a comprehensive survey of various topics, including bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics. The book also discusses strategies for improving stakeholder relations, designing ethical clinical trials, avoiding conflicts of interest, and establishing ethics advisory boards. With contributions from experts across disciplines such as law, medicine, and bioinformatics, this edition serves as a resource for understanding the intersection of ethics and biotechnology.
Official synopsis Publisher
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
Author
Publisher
Topics
FAQ
What is “BioIndustry Ethics” about?
Who is the author of “BioIndustry Ethics”?
When was “BioIndustry Ethics” published?
What is the ISBN for “BioIndustry Ethics”?
What are the book details (language, pages, edition)?
